Evidence map›Paper›PMID 30651141›Full record

ArticleArthritis research & therapy2019

Minimal Clinically Important Differences for the Modified Rodnan Skin Score: Results from the Scleroderma Lung Studies (SLS-I and SLS-II).

Dinesh Khanna, Philip J Clements, Elizabeth R Volkmann, Holly Wilhalme, Chi-Hong Tseng, Daniel E Furst, Michael D Roth, Oliver Distler, Donald P Tashkin

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Arthritis research & therapy, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
25citing papers in PubMed, 4 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

25 citing papers in PubMed, 4 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Stem cell transplantation for systemic sclerosis.The Cochrane database of systematic reviews · 2022
    Pooled it
  5. Trial
  6. Trial
  7. Trial
  8. Trial
  9. Trial
  10. Trial
  11. Trial
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Lysophosphatidic acid receptor 1 inhibition: a potential treatment target for pulmonary fibrosis.European respiratory review : an official journal of the European Respiratory Society · 2024
    Review
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Dinesh KhannaDepartment of Medicine, University of Michigan, Ann Arbor, MI, 48105, USA. khannad@umich.edu.ORCID 0000-0003-1412-4453
Philip J ClementsDepartment of Medicine, David Geffen School of Medicine at University of California, Los Angeles, CA, USA.
Elizabeth R VolkmannDepartment of Medicine, David Geffen School of Medicine at University of California, Los Angeles, CA, USA.
Holly WilhalmeDepartment of Medicine, David Geffen School of Medicine at University of California, Los Angeles, CA, USA.
Chi-Hong TsengDepartment of Medicine, David Geffen School of Medicine at University of California, Los Angeles, CA, USA.
Daniel E FurstDepartment of Medicine, David Geffen School of Medicine at University of California, Los Angeles, CA, USA.
Michael D RothDepartment of Medicine, David Geffen School of Medicine at University of California, Los Angeles, CA, USA.
Oliver DistlerDepartment of Rheumatology, University Hospital Zurich, Zurich, Switzerland.
Donald P TashkinDepartment of Medicine, David Geffen School of Medicine at University of California, Los Angeles, CA, USA.

Funding

UCLA Clinical Translational Science InstituteUL1TR001881 · NCATS · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI ARLEEN F. BROWN, ARASH NAEIM · 2016 to 2026
$118.1M
MOCSLID-DCCR01HL089901 · NHLBI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI ELASHOFF, ROBERT M · 2008 to 2012
$9.1M
SCLERODERMA LUNG STUDYU01HL060587 · NHLBI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI TASHKIN, DONALD P · 1999 to 2003
$2.3M
MOCSLID-CCCR01HL089758 · NHLBI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI TASHKIN, DONALD P · 2008 to 2012
$2.0M
Outcomes Research in Rheumatic DiseasesK24AR063120 · NIAMS · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI KHANNA, DINESH · 2012 to 2022
$1.6M
SCLERODERMA LUNG STUDYU01HL060606 · NHLBI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI ELASHOFF, ROBERT M · 1999 to 2006
$1.3M
NCATS NIH HHS UL1 TR001881NHLBI NIH HHS R01 HL089758NHLBI NIH HHS R01 HL089901NHLBI NIH HHS U01 HL060587NHLBI NIH HHS U01 HL060606NIAMS NIH HHS K24 AR063120
6 · The paper itself

Abstract

objectiveThis study aimed to assess the minimal clinically important differences (MCIDs) for the modified Rodnan skin score (mRSS) using combined data from the Scleroderma Lung Studies (I and II).

methodsMCID estimates for the mRSS at 12 months were calculated using three anchors: change in scores on the Health Assessment Questionnaire- Disability Index from baseline to 12 months, change in scores on the Patient Global Assessment from baseline to 12 months, and answer at 12 month for the Short Form-36 health transition question "Compared to one year ago, how would you rate your health in general now?" We determined the mRSS MCID estimates for all participants and for those with diffuse cutaneous systemic sclerosis (dcSSc). We then assessed associations between MCID estimates of mRSS improvement and patient-reported outcomes, using Student's t test to compare the mean differences in patient outcomes between those who met the MCID improvement criteria versus those who did not meet the improvement criteria.

resultsThe mean (SD) mRSS at baseline was 14.75 (10.72) for all participants and 20.93 (9.61) for those with dcSSc. The MCID estimate for mRSS improvement at 12 months ranged from 3 to 4 units for the overall group (improvement of 20-27% from baseline) and was 5 units for those with dcSSc (improvement of 24% from baseline). Those who met the mRSS MCID improvement criteria had statistically significant improvements in scores on the Short Form-36 Physical Component Summary, the Transition Dyspnea Index, and joint contractures at 12 months.

conclusionMCID estimates for the mRSS were 3-4 units for all participants and 5 units for those with dcSSc. These findings are consistent with previously reported MCID estimates for systemic sclerosis.

Indexed as

Minimal Clinically Important DifferenceSeverity of Illness IndexAdultAntineoplastic AgentsCyclophosphamideFemaleHumansLung DiseasesMaleMiddle AgedMycophenolic AcidOutcome Assessment, Health CareScleroderma, DiffuseScleroderma, SystemicSkinSurveys and QuestionnairesAntineoplastic AgentsCyclophosphamideMycophenolic AcidInterstitial lung diseaseMinimal clinically important differenceModified Rodnan skin scoreSclerodermaSkin thicknessSystemic sclerosis

Identifiers

PMID30651141
PMCPMC6335851

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.